华大基因：预计2025年全年净亏损5.30亿元—6.30亿元

Core Viewpoint - The company, BGI Genomics, anticipates a significant net loss for the year 2025, projecting a net profit attributable to shareholders of between -630 million yuan and -530 million yuan, indicating a loss of 5.30 billion to 6.30 billion yuan [1] Financial Performance - The expected operating revenue for 2025 is approximately 3.6 billion to 3.9 billion yuan, reflecting a year-on-year change of -6.90% to 0.86% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -675 million yuan and -545 million yuan [1] Business Segment Analysis - The reproductive health business is expected to see a decline in revenue compared to 2024, primarily due to decreased market demand and the implementation of centralized procurement policies [1] - The company is focusing on high-margin products in the non-invasive prenatal testing (NIPT) segment to counteract the price decline of basic NIPT products [1] - Revenue from the auxiliary clinical diagnosis of genetic diseases within the three-level prevention business has shown steady growth year-on-year [1] - The oncology and chronic disease prevention business is projected to decline due to fluctuations in demand from commercial health check clients and the timing of contract renewals for public health projects [1] - The infection control business has achieved robust growth, with revenue from PTseq products doubling year-on-year, supported by a comprehensive pathogen detection technology system [1] Strategic Adjustments - The company is actively adjusting its global technology service business layout to mitigate external uncertainties, focusing on core markets and high-value clients [1] - The single-cell sequencing business has experienced significant year-on-year revenue growth [1] - The company is transitioning its independent medical laboratory (ICL) to an in vitro diagnostic (IVD) model in response to changes in industry sample management policies [1] Cost Management and Credit Control - The company is implementing measures to strengthen credit control and improve collection efforts, including legal actions and asset swaps [1] - Strategic adjustments to delivery centers and resource allocation have led to impairment provisions, contributing to the anticipated losses [1] - The company expects a significant reduction in sales, management, and R&D expenses through lean operations [1] Non-Recurring Gains and Losses - Non-recurring gains and losses are expected to impact net profit by approximately 15 million to 45 million yuan, primarily from subsidiary disposals and government subsidies [1]